Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Copper Histidine · 1 trial · 3 indications
Neurological Improvement: reduction in dysautonomia symptoms in OHS, and improved nerve conduction tests in unexplained copper deficiency
| Name | Type | Description |
|---|---|---|
| Copper Histidine | DRUG | Daily subcutaneous injections for three years |
* INCLUSION CRITERIA: In order to be eligible to participate in this study, an individual must meet all of the following criteria: 1. Provision of signed and dated informed consent form by parent or legal guardian, or the subject himself/herself. 2. Male or female, aged 0 to 80 years. 3. Diagnosed...
Copper Histidine is an investigational small molecule being studied for the treatment of Menkes Disease, a genetic disorder that affects copper levels in the body. It is also being researched in related conditions such as Occipital Horn Syndrome and unexplained copper deficiency.
Copper Histidine is being developed by Fortress Biotech, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol FBIO. The company is advancing this investigational therapy for Menkes Disease.
Copper Histidine is in Phase 3 clinical development. It is an investigational drug and has not been approved by the FDA. The Phase 3 trial has been completed, and the drug remains under clinical investigation for Menkes Disease.
Copper Histidine has been studied in one completed Phase 3 clinical trial with the identifier NCT00811785. This trial enrolled 93 participants and investigated the molecular bases of response to copper treatment in Menkes Disease, related phenotypes, and unexplained copper deficiency.
Copper Histidine is also known as copper histidinate. Both names refer to the same investigational compound being developed by Fortress Biotech for the treatment of Menkes Disease.